Bandwidth Inc vs Medpace Holdings Inc — how do they compare? Bandwidth Inc trades at $51.42 (market cap $1.66B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 10.2× Bandwidth Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Bandwidth Inc nearer its low. Which is the better fit depends on your goals.
| BAND | MEDP | |
|---|---|---|
Market Cap | $1.66B | $16.90B |
Sector | Technology | Technology |
52-Week High | $78.44 | $620.59 |
52-Week Low | $12.82 | $393.42 |
Enterprise Value | $2.04B | $16.52B |
Signals from Pluang's Aura AI — not financial advice
Bandwidth (BAND) trades at $51.97, down 1.4% over 24 hours, with a bullish technical outlook supported by moving averages despite overbought RSI signals. The company reported strong Q2 2026 results, beating EPS estimates with $0.37 versus $0.3652 expected, and raised its full-year outlook on AI-driven demand growth. Revenue climbed 22% year-over-year to $220 million, though net income margins remain thin at 0.27% for 2026.
The stock offers upside to the $75.25 analyst consensus target, fueled by AI adoption and enterprise wins, but risks include high valuation multiples like a 34.08 EV/EBITDA and competitive pressures in cloud communications. Execution on profitability improvements will be critical for sustaining gains.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →